StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.04−0.14 (-11.86%)

Close on Nov 16, 2026Market cap $104.35MP/E –Yield –

Cellectis r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $93.52M, up 3.3% from the year before. Over ten years it grew 4.9% a year on average. The highest annual figure on record is $117.84M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$93.52M+3.3%
FY2024Dec 31, 2024$90.54M+3.3%
FY2023Dec 31, 2023$87.65M-10.1%
FY2022Dec 31, 2022$97.50M-17.3%
FY2021Dec 31, 2021$117.84M+52.9%
FY2020Dec 31, 2020$77.05M-16.3%
FY2019Dec 31, 2019$92.04M+20.2%
FY2018Dec 31, 2018$76.57M-3.4%
FY2017Dec 31, 2017$79.23M+1.0%
FY2016Dec 31, 2016$78.46M+34.9%
FY2015Dec 31, 2015$58.15M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$24.98M-2.6%
Q2 FY2025Jun 30, 2025$23.08M-25.9%
Q2 FY2024Jun 30, 2024$23.52M+2.9%
Q2 FY2023Jun 30, 2023$22.20M-12.7%
Q2 FY2022Jun 30, 2022$25.63M–
Q2 FY2021Jun 30, 2021$31.15M–
Q2 FY2020Jun 30, 2020$22.86M–
Q2 FY2019Jun 30, 2019$25.42M–

More Cellectis figures

See a number that looks wrong?